Advanced search
Publication Cover
Human Vaccines Volume 6, 2010 - Issue 11
Journal homepage
862
Views
29
CrossRef citations to date
0
Altmetric
Research Paper

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine

Randomized double-blind phase II evaluation of safety and immunogenicity

Peter E Nasveld Australian Army Malaria Institute, Queensland, Australia
,
Joanne Marjason Q-Pharm, Clive Berghofer Cancer Research Centre, Queensland, Australia
,
Sonya Bennett Australian Army Malaria Institute, Queensland, Australia
,
John Aaskov Australian Army Malaria Institute, Queensland, Australia
,
Suzanne Elliott Q-Pharm, Clive Berghofer Cancer Research Centre, Queensland, Australia
,
Karen McCarthy Acambis Inc, Cambridge, UK/Massachusetts USA
,
Niranjan Kanesa-thasan Acambis Inc, Cambridge, UK/Massachusetts USA
,
Emmanuel Feroldi Sanofi Pasteur, Marcy L’Etoile, France
&
Mark Reid Australian Army Malaria Institute, Queensland, Australia Correspondence[email protected]
 show all
Pages 906-914 | Published online: 01 Nov 2010

References

  • Tsai TF, Yu XY. Plotkin SA, Mortimer EA. Japanese encephalitis vaccines. Vaccines 1994; Second edition Philadelphia, PA WB Saunders 671 - 714
  • Oya A. Japanese encephalitis vaccine. Act Pediatri Jpn 1998; 30:175 - 184
  • Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laoraka-pongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1998; 319:608 - 614
  • DeFraites RF, Gambel JM, Hoke CH Jr, Sanchez SL, Withers BG, Karabatsos N, et al. Japanese encephalitis vaccine (inactivated, biken) in US soldiers: immunogenicity and safety of vaccine in two dosing regimens. Am J Trop Med Hyg 1999; 61:288 - 293
  • Gambel JM, DeFraites R, Hoke C, Brown A, Sanchez J, Karabatsos N, et al. Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series. J Infect Dis 1995; 171:1074
  • Tsai TF, Chang GJ, Yu YX. Plotkin SA, Orenstein WA. Japanese encephalitis vaccines. Vaccines 1999; third edition Philadelphia, PA WB Saunders 672 - 710
  • Ruff TA, Eisen D, Fuller A, Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 1991; 338:881 - 882
  • Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting Bangkok, Thailand 13–15 October 1998. Vaccine 2000; 18:1 - 25
  • Nimmannitya S, Hutamai S, Kalayanarooj S, Rojanasuphot S. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines. Southeast Asian J Trop Med Public Health 1995; 26:689 - 693
  • Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999; 73:3095 - 3101
  • Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, et al. Clinical proof of principle for chimerivax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004 - 1018
  • Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (chimerivax-je): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188:1213 - 1230
  • Johnson C, Monath TP, Kanesa-thasan N, Mathis D, Miller C, Shapiro S, et al. Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum Vaccin 2005; 1:24 - 29
  • Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, et al. Recombinant, chimaeric live, attenuated vaccine (chimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever 17D-204 virus is safe, immunogenic and protective in non-human primates. Vaccine 1999; 17:1869 - 1882
  • Ku CC, King CC, Lin CY, Hsu HC, Chen LY, Yueh YY, et al. Homologous and heterologous neutralization of antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J Med Virol 1994; 44:122 - 131
  • Halstead SB, Jacobson J. Plotkin S, Orenstein W, Offit P. Japanese encephalitis vaccines. Vaccines 2004; 4th edition Philadelphia, PA Saunders Elsevier 311 - 352
  • Hennessy S, Zhengie L, Tsai TF, Strom BL, Chao-Min W, Hui-Lian L, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case control study. Lancet 1996; 347:1583 - 1586
  • Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, et al. Efficacy of a single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001; 358:791 - 795
  • Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 2005; 366:1375 - 1378
  • Tandan JB, Ohrr H, Young MS, Yoksan S, Ji M, Nam CM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization. Vaccine 2007; 25:5041 - 5045
  • Beasley DWC, Li L, Suderman MT, Guirakhoo F, Trent DW, Monath TP, et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera against ChimeriVax™-JE experimental vaccine. Vaccine 2004; 22:3722 - 3726
  • Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285 - 290

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.